Aytu BioPharma Balance Sheet Health
Financial Health criteria checks 5/6
Aytu BioPharma has a total shareholder equity of $32.9M and total debt of $16.0M, which brings its debt-to-equity ratio to 48.7%. Its total assets and total liabilities are $131.2M and $98.4M respectively.
Key information
48.7%
Debt to equity ratio
US$16.00m
Debt
| Interest coverage ratio | n/a |
| Cash | US$19.53m |
| Equity | US$32.85m |
| Total liabilities | US$98.40m |
| Total assets | US$131.25m |
Recent financial health updates
Recent updates
US$8.00 - That's What Analysts Think Aytu BioPharma, Inc. (NASDAQ:AYTU) Is Worth After These Results
Feb 17
Aytu BioPharma, Inc. (NASDAQ:AYTU) Surges 25% Yet Its Low P/S Is No Reason For Excitement
Feb 16Does Aytu BioPharma (NASDAQ:AYTU) Have A Healthy Balance Sheet?
Jan 23Aytu BioPharma, Inc.'s (NASDAQ:AYTU) Share Price Boosted 59% But Its Business Prospects Need A Lift Too
Sep 29Aytu stock falls amid suspending clinical programs to save costs
Oct 13Aytu BioScience GAAP EPS of -$0.49 misses by $0.12, revenue of $27.45M beats by $1.95M
Sep 27Aytu Biopharma adds fourth patent license for AR101 to treat rare genetic disorder
Sep 14Aytu gets US patent for AR101/Enzastaurin for circulatory system disorders
Aug 16Aytu BioPharma plunges on pricing $10M stock and warrants offering
Aug 09Earnings Release: Here's Why Analysts Cut Their Aytu BioPharma, Inc. (NASDAQ:AYTU) Price Target To US$8.00
May 19Is Aytu Biopharma (NASDAQ:AYTU) Using Debt In A Risky Way?
Sep 11Aytu BioPharma up 21% in afternoon trading
Jun 21Increases to Aytu Biopharma, Inc.'s (NASDAQ:AYTU) CEO Compensation Might Cool off for now
May 15A Quick Analysis On Aytu BioScience's (NASDAQ:AYTU) CEO Compensation
Feb 14Aytu BioScience: Time To Call In The Cavalry Of Value Catalysts
Dec 31Aytu BioScience completes safety study in critically ill COVID-19 patients
Dec 28Aytu Bio raises 'bought deal' offering to $25M
Dec 11Aytu BioScience: The Barcode King Is Poised For An Epic Breakout
Nov 12Financial Position Analysis
Short Term Liabilities: AYTU's short term assets ($71.4M) exceed its short term liabilities ($64.2M).
Long Term Liabilities: AYTU's short term assets ($71.4M) exceed its long term liabilities ($34.2M).
Debt to Equity History and Analysis
Debt Level: AYTU has more cash than its total debt.
Reducing Debt: AYTU's debt to equity ratio has increased from 25.3% to 48.7% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: Whilst unprofitable AYTU has sufficient cash runway for more than 3 years if it maintains its current positive free cash flow level.
Forecast Cash Runway: AYTU is unprofitable but has sufficient cash runway for more than 3 years, due to free cash flow being positive and growing by 1.5% per year.